Biogen Inc
NASDAQ:BIIB

Watchlist Manager
Biogen Inc Logo
Biogen Inc
NASDAQ:BIIB
Watchlist
Price: 132.235 USD 0.83%
Market Cap: 19.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+31%
Revenue
Forecast
-1%
Operating Income
Forecast
+4%
Net Income
Forecast
+14%

Wall Street
Price Targets

BIIB Price Targets Summary
Biogen Inc

Wall Street analysts forecast BIIB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIIB is 173.341 USD with a low forecast of 116.15 USD and a high forecast of 273 USD.

BIIB Lowest Forecast
Wall Street Target
116.15 USD
12% Downside
BIIB Average Forecast
Wall Street Target
173.341 USD
31% Upside
BIIB Highest Forecast
Wall Street Target
273 USD
106% Upside
Lowest
Price Target
116.15 USD
12% Downside
Average
Price Target
173.341 USD
31% Upside
Highest
Price Target
273 USD
106% Upside
Biogen Inc Competitors:
Price Targets
DSGN
Design Therapeutics Inc
86% Upside
TSHA
Taysha Gene Therapies Inc
161% Upside
1530
3SBio Inc
7% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
32% Upside
DSGN
Design Therapeutics Inc
86% Upside
TSHA
Taysha Gene Therapies Inc
161% Upside
1530
3SBio Inc
7% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
32% Upside
NBIX
Neurocrine Biosciences Inc
27% Upside
IONS
Ionis Pharmaceuticals Inc
69% Upside
COV
Covalon Technologies Ltd
59% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
17% Downside

Revenue
Forecast

Revenue Estimate
Biogen Inc

For the last 8 years the compound annual growth rate for Biogen Inc's revenue is -2%. The projected CAGR for the next 3 years is -1%.

-2%
Past Growth
-1%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Biogen Inc

For the last 8 years the compound annual growth rate for Biogen Inc's operating income is -9%. The projected CAGR for the next 3 years is 4%.

-9%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Biogen Inc

For the last 8 years the compound annual growth rate for Biogen Inc's net income is -10%. The projected CAGR for the next 3 years is 14%.

-10%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-20%
Average Miss
What are analyst estimates?

See Also

Summary
BIIB intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIIB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIIB stock valuation using valuation multiples.
Wall Street Estimates
BIIB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIIB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BIIB's stock price target?
Price Target
173.341 USD

According to Wall Street analysts, the average 1-year price target for BIIB is 173.341 USD with a low forecast of 116.15 USD and a high forecast of 273 USD.

What is Biogen Inc's Revenue forecast?
Projected CAGR
-1%

For the last 8 years the compound annual growth rate for Biogen Inc's revenue is -2%. The projected CAGR for the next 3 years is -1%.

What is Biogen Inc's Operating Income forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Biogen Inc's operating income is -9%. The projected CAGR for the next 3 years is 4%.

What is Biogen Inc's Net Income forecast?
Projected CAGR
14%

For the last 8 years the compound annual growth rate for Biogen Inc's net income is -10%. The projected CAGR for the next 3 years is 14%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 259,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.